Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy

– Clinically Meaningful Benefit Observed at Both ATH434 Doses Studied –

– Achieved Statistical Significance with Up to 48% Slowing of Clinical Progression on UMSARS Rating Scale –